4//SEC Filing
DAVIS MONTY L 4
Accession 0001000229-18-000013
CIK 0001000229other
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 6:08 PM ET
Size
9.2 KB
Accession
0001000229-18-000013
Insider Transaction Report
Form 4
Transactions
- Exercise/Conversion
Performance Shares
2017-12-29−17,685→ 0 totalExercise: $0.00→ Common Shares (17,685 underlying) - Exercise/Conversion
Common Shares
2017-12-29+17,685→ 108,619 total - Tax Payment
Common Shares
2017-12-29$109.55/sh−6,107$669,022→ 102,512 total
Holdings
- 15,218(indirect: By 401(k))
Common Shares
Footnotes (1)
- [F1]The shares vesting were awarded as restricted performance shares in February 2015 as reported in the Form 4 filing on February 17, 2015. This filing states that 80% of the restricted performance shares will vest only upon the Company's return on invested capital being in the top decile among the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period, with the remaining 20% vesting if the Company is the top ROIC performer. The Company was the top performing ROIC company as of the end of the performance period and as such the performance criteria and all requirements for full vesting have been met and thus 100% of the shares vested on December 29, 2017, at the conclusion of the performance period.
Documents
Issuer
CORE LABORATORIES N V
CIK 0001000229
Entity typeother
Related Parties
1- filerCIK 0001282548
Filing Metadata
- Form type
- 4
- Filed
- Jan 2, 7:00 PM ET
- Accepted
- Jan 3, 6:08 PM ET
- Size
- 9.2 KB